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INTRODUCTION
Year after year, more and more so-called new psychoactive substances (NPS) enter the drugs of abuse (DOA) market with 803 different substances being reported to the United Nations Office on Drugs and Crime in the period 2009-2017. 1, 2 Many NPS show psychoactive effects similar to drugs under international control and are often sold via the Internet. 1 Although NPS are initially not controlled and easily available, they can pose a significant health risk and reports about adverse effects are frequently available. [3] [4] [5] [6] One of the challenges when dealing with this phenomenon is the lack of knowledge concerning pharmacokinetics and toxicity since they are marketed without (pre)clinical safety studies. 7 The 2C-series drugs of abuse (2Cs) are phenethylamine derivatives that commonly exhibit a primary amine functionality separated from the phenyl ring by two carbon atoms, which differs from their amphetamine counterparts that show a methyl group at the alphaposition (3Cs) (Figure 1 ). Within a 2,5-dimethoxyphenethylamine nucleus, a lipophilic substituent is commonly present in position 4. 8 In the so-called FLY series, the methoxy groups are rigidified into a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran core. 9 A number of 2Cs have shown psychostimulant and hallucinogenic properties and information gathered from casework suggests that intoxicated patients might exhibit either a sympathomimetic toxidrome, serotonin (5-HT) toxicity, hallucinogenesis, or combinations thereof. 10 The available information on the pharmacology of 2Cs indicates that the interaction with serotonin receptor subtypes is one of the pharmacological features linked to these substances. 9, [11] [12] [13] [14] Partial agonism at alpha-1 adrenergic receptors has also been described for 2C-B. 15 In addition, the re-uptake inhibition of the monoamines norepinephrine and 5-HT into rat brain synaptosomes was described for 2,5dimethoxy-4-ethylphenetylamine (2C-E) and 2C-I. 16 At the same time, monoamine oxidase (MAO) inhibition may also lead to elevated monoamine levels that have been associated with adverse events described in cases of 2C intoxications, which included agitation, nausea, vomiting, tachycardia, hypertension, or seizures. 10, [17] [18] [19] The aim of this study was to extend the knowledge surrounding the potential of MAO inhibition (and to determine their IC 50 values) for 17 test drugs, which consisted of twelve 2Cs (2C-B, 2C-D, 2C-E, 2C-H, 2C-I, 2C-N, 2C-P, 2C-T-2, 2C-T-7, 2C-T-21, bk-2C-B and bk-2C-I) and five FLY analogs (2C-B-FLY, 2C-E-FLY, 2C-EF-FLY, 2C-I-FLY, 2C -T-7-FLY) ( Figure 1 ). A previously published MAO inhibition assay based on heterologously expressed enzymes and hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry (HILIC-HRMS/MS) was applied for this purpose. MAO activity should be assessed using kynuramine (KYN) as the non-selective substrate as the formation of the corresponding aldehyde is catalyzed by MAO-A and B and followed by non-enzymatic condensation to the product 4-hydroxyquinoline (4-OHC).
EXPERIMENTAL

Chemicals and enzymes
The baculovirus-infected insect cell microsomes (Supersomes) containing human complementary DNA-expressed MAO-A or MAO-B (5 mg protein/mL) and wild-type Supersomes without MAO activity as negative control (MAO control, 5 mg protein/mL) were obtained from Corning (Amsterdam, The Netherlands). After delivery, enzyme preparations were thawed at 37°C, aliquoted, snap-frozen in liquid nitrogen, and stored at -80°C until use. µM, MAO-B: 23 µM), and 10 µM of one of the potential inhibitors as described before. 20 
Amphetamine
Initial MAO inhibition screening
Reactions
were initiated by addition of the ice-cold enzyme dilution, incubated for 20 min at 37°C, and stopped with 30 µL of ice-cold acetonitrile containing 10 µM amphetamine-d 5 as internal standard (IS). The mixture was centrifuged for 2 min at 10,000 g, 50 µL of the supernatant were transferred to an autosampler vial, and injected onto the HILIC-HRMS/MS apparatus for analysis. All incubations were performed in triplicate (n = 3). In addition to these samples, reference samples without inhibitor, positive control samples with known inhibitors (MAO-A: 5-IT, MAO-B: selegiline, 10 µM, each), blank samples without MAO activity, and interfering samples were also prepared in triplicate. Interfering samples were incubated reference samples without inhibitor and terminated with ice-cold acetonitrile containing the IS and the test drugs each at a concentration of 10 µM. A simplified scheme of the initial inhibition screening procedure is given in Figure 2 . The 4-OHC amount, given as the peak area ratio of 4-OHC and the IS, in blank samples without MAO 
Determination of IC 50 values
MAO-A or B were incubated with the following 10 inhibitor concentrations: 2, 5, 10, 20, 39, 78, 156, 313, 625, 1250 µM, with the exception of 2C-H that was used in lower concentrations (0.04, 0.08, 0.15, 0.3, 0.6, 1, 2, 5, 10, 20 µM). All incubations were performed in duplicate (n = 2). All other incubation conditions were the same as described above. Reference and blank samples were also prepared as described above. The IC 50 values were calculated by plotting the 4-OHC formation expressed as MAO activity (relative to reference samples) over the logarithm of the inhibitor concentration using GraphPad Prism 5.00.
HILIC-HRMS/MS conditions
Apparatus and conditions were the same as already described. 20 automated peak integration were as follows: peak detection algorithm, ICIS; area noise factor, 5;
and peak noise factor, 300. GraphPad QuickCalcs was used for outlier detection (http://graphpad. com/quickcalcs/grubbs1), while GraphPad Prism 5.00 was used for statistical evaluation.
RESULTS AND DISCUSSION
Initial MAO inhibition screening
Formation of 4-OHC was measured using HILIC-HRMS/MS and the complete analytical procedure was already previously successfully validated. 20 The results of the initial MAO inhibition screening of the 2Cs are summarized in Figure 3 . Suitable incubation conditions were verified using positive control samples with known inhibitors (see Figure 2 ). 5-IT reduced MAO-A activity by more than 90%, while selegiline almost completely inhibited MAO-B activity, which was in agreement with the previous study. 20 As only 4-OHC, KYN, and the IS were detected by the analytical method, it was mandatory to exclude analytical interferences, such as ion suppression or enhancement caused by potentially co-eluting test drugs. Therefore, MAO activity determined from the interfering samples was compared to that in the reference samples. The test compounds caused no analytical interferences.
For thirteen test drugs, MAO-A inhibition was observed to some degree. Seven of these drugs highly significant (***, P < 0.001). However, only 2C-H reduced MAO-B activity by more than 50%, which resulted in a corresponding IC 50 value below 10 µM (Table 1 ).
Determination and comparison of IC 50 values
In order to save time and costs, IC 50 values for MAO-A and B inhibition were only determined in cases where the test drugs revealed a statistically highly significant (***, P < 0.001) inhibition during the initial screening phase. All incubations for the IC 50 value determinations were performed in duplicate, in contrast to triplicate incubations during the initial MAO inhibition screening, to reduce workload and number of samples in accordance with the previous study. 20 As far as the potential clinical relevance of MAO inhibition based on IC 50 values was concerned, plasma concentrations obtained from the case report literature (Table 1) subsequently performed in postmortem samples. 19 The IC 50 values determined in this study were higher than the plasma concentrations reported for 2C-P and 2C-T-7. However, as they were measured in individual cases, their significance remains unclear. Shulgin and Shulgin published their experiences with numerous phenethylamines, which included information about synthesis, dosage and duration of effects. 8 These data are available for all 2Cs tested in this study with exception of the two bk-2Cs and FLY analogs. For some compounds, such as 2C-D or 2C-N, higher doses were described than those estimated in the previously mentioned case reports. Consequently, higher doses are expected to lead to higher plasma concentrations. However, it must be considered that concentrations detectable in certain tissues are often higher than in plasma due to lipophilicity or active transport processes. A brain-to-plasma concentration ratio of 13.9 was described for 2C-B in rats. 30 Elevated concentrations in the liver, the main metabolizing organ, are also more than likely to be encountered. 31 From this perspective, a contribution to the clinical effects of MAO inhibition can perhaps not be excluded. 33 MAO-A and B were shown to be the predominant enzymes involved in formation of their aldehydes and the studied 2Cs had a higher affinity to MAO-A than B. 33 As the present study identified these compounds with exception of 2C-T-2 as inhibitors of MAO-B, a competitive inhibition mechanism might be possible.
2C
Nevertheless, as some 2Cs and 2C-B-FLY were described to have affinities to 5-HT receptor subtypes within the nM range 9, [11] [12] [13] [14] , MAO IC 50 values within the µM range are expected to play only a minor role in the pharmacological effects after consumption of recreational doses. However, a contribution of MAO inhibition to the clinical effects observed in intoxication cases cannot be excluded.
CONCLUSIONS
The presented study identified various 2C-, and FLY-related test drugs as MAO inhibitors. A previously published inhibition assay was successfully applied for initial inhibition screening 
